PBYI Stock Overview
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Puma Biotechnology, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.83 |
| 52 Week High | US$7.73 |
| 52 Week Low | US$2.13 |
| Beta | 1.31 |
| 1 Month Change | -13.60% |
| 3 Month Change | -2.42% |
| 1 Year Change | 85.77% |
| 3 Year Change | -52.65% |
| 5 Year Change | -84.60% |
| Change since IPO | -64.22% |
Recent News & Updates
Recent updates
Is There An Opportunity With Puma Biotechnology, Inc.'s (NASDAQ:PBYI) 46% Undervaluation?
Apr 10
There's Reason For Concern Over Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Massive 31% Price Jump
Mar 01Here's Why Puma Biotechnology (NASDAQ:PBYI) Has A Meaningful Debt Burden
Dec 27Puma Biotechnology (NASDAQ:PBYI) Has A Somewhat Strained Balance Sheet
Sep 08Puma Biotechnology, Inc. (NASDAQ:PBYI) Held Back By Insufficient Growth Even After Shares Climb 34%
Apr 17We Think Puma Biotechnology (NASDAQ:PBYI) Can Stay On Top Of Its Debt
Dec 14Puma Biotechnology, Takeda enter licensing agreement for cancer treatment alisertib
Sep 20Puma Biotechnology (NASDAQ:PBYI) Takes On Some Risk With Its Use Of Debt
Sep 05Puma Biotechnology Non-GAAP EPS of $0.28, revenue of $59.5M
Aug 04Is Puma Biotechnology (NASDAQ:PBYI) Using Debt Sensibly?
Jun 04Puma Bio: Still Worthy Of Consideration After Earnings Surprise
Mar 08Puma Bio: Recent Sell-Off Brings My Position Out Of Mothball
Aug 13Shareholder Returns
| PBYI | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -6.6% | 1.5% | 1.2% |
| 1Y | 85.8% | 1.1% | 24.7% |
Return vs Industry: PBYI exceeded the US Biotechs industry which returned 1.1% over the past year.
Return vs Market: PBYI exceeded the US Market which returned 24.7% over the past year.
Price Volatility
| PBYI volatility | |
|---|---|
| PBYI Average Weekly Movement | 12.1% |
| Biotechs Industry Average Movement | 11.7% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: PBYI's share price has been volatile over the past 3 months.
Volatility Over Time: PBYI's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 185 | Alan Auerbach | www.pumabiotechnology.com |
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer.
Puma Biotechnology, Inc. Fundamentals Summary
| PBYI fundamental statistics | |
|---|---|
| Market cap | US$247.30m |
| Earnings (TTM) | US$21.59m |
| Revenue (TTM) | US$235.64m |
10.8x
P/E Ratio1.0x
P/S RatioIs PBYI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PBYI income statement (TTM) | |
|---|---|
| Revenue | US$235.64m |
| Cost of Revenue | US$62.68m |
| Gross Profit | US$172.96m |
| Other Expenses | US$151.36m |
| Earnings | US$21.59m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 02, 2024
| Earnings per share (EPS) | 0.45 |
| Gross Margin | 73.40% |
| Net Profit Margin | 9.16% |
| Debt/Equity Ratio | 186.5% |
How did PBYI perform over the long term?
See historical performance and comparison